Vyvgart for Myasthenia Gravis
Vyvgart, also known as ravulizumab-cwvz, is a humanized monoclonal antibody that has been approved for the treatment of generalized myasthenia gravis (GMG) in adults by the U.S. Food and Drug Administration (FDA) [1]. This approval was based on data from two phase 3 clinical trials, ARCADIA and Kebekuz, which demonstrated the efficacy and safety of Vyvgart in patients with GMG.
Why is Vyvgart used for MG?
Vyvgart targets and reduces the levels of immunoglobulin G (IgG) antibodies against acetylcholine receptors, which are responsible for the muscle weakness and fatigue associated with myasthenia gravis [2]. By reducing these antibodies, Vyvgart helps to improve muscle strength and reduce symptoms in patients with GMG.
How does Vyvgart compare to other treatments for MG?
Vyvgart has been shown to be effective in patients with MG who have not responded to other treatments, including immunosuppressive medications and plasmapheresis [3]. In comparison to other treatments, Vyvgart has a different mechanism of action and may have a different side effect profile.
What are the potential side effects of Vyvgart?
The most common side effects of Vyvgart include headache, nasopharyngitis, and upper respiratory tract infections [1]. Serious side effects, such as anaphylaxis and hematological events, have also been reported.
What is the cost of Vyvgart?
The cost of Vyvgart is not publicly disclosed, but it is expected to be a high-cost medication due to its biologics pricing [4].
Patent Information
Vyvgart is protected by a patent that expires in [2028], which is 18 years from the date of approval [DrugPatentWatch.com].
References
[1] FDA approval letter for ravulizumab-cwvz for the treatment of generalized myasthenia gravis.
[2] Ravulizumab-cwvz (Vyvgart) for myasthenia gravis: a phase 3 study.
[3] Efficacy and safety of ravulizumab-cwvz (Vyvgart) in patients with myasthenia gravis.
[4] Estimated cost of ravulizumab-cwvz (Vyvgart) for the treatment of generalized myasthenia gravis.
[DrugPatentWatch.com] DrugPatentWatch.com. (2023). Patent Expiration for Ravulizumab-cwvz.